GLP-1 Injections Under Scrutiny: Why Medical Oversight Matters More Than Ever
The conversation around GLP-1 weight loss injections has reached a critical point.
In a recent interview on Goeiemôre Good Morning, aesthetic practitioner Dr David Grieve joined the discussion following a controversial report involving the sale and marketing of GLP-1 medications such as Ozempic and Mounjaro by non-medical individuals.
What began as a single complaint has opened up a much broader and more pressing industry conversation.
At the heart of the discussion lies a key question: Who should be allowed to prescribe, sell, and administer these treatments?
As demand for rapid weight loss solutions continues to surge, GLP-1 agonists have become one of the most talked-about treatments across both medical and aesthetic spaces. However, with popularity has come confusion, misinformation, and growing concern around patient safety.
Dr Grieve addressed a number of critical issues, including the misconception that peptides and similar products fall into the same category as over-the-counter supplements. In reality, these are potent medical treatments that require proper clinical oversight, patient assessment, and ongoing monitoring.
The risks of unsupervised use are not insignificant. From unmanaged side effects to inappropriate patient selection, the consequences of incorrect use can be severe, particularly when treatments are administered outside of a regulated medical framework.
Beyond the clinical risks, the discussion also touched on a wider industry trend: the increasing normalisation of “quick-fix” solutions driven by social media demand. While patient interest continues to grow, so too does the responsibility on practitioners and regulatory bodies to ensure ethical practice and patient-first care.
Dr Grieve’s message was clear. There is an urgent need for clarity, regulation, and accountability within this rapidly evolving space.
Hear More at the Aesthetic Medicine Convention
Dr David Grieve will be speaking at the Aesthetic Medicine Convention Johannesburg, where he will expand on these critical topics as part of the Qualified Medical Practitioners Programme.
📅 Day 1 – 15 May 2026 🕒 11:00 – 13:00 📍 Peptides: The Future of Aesthetic Medicine
Topic: Regulatory Landscape and Patient Safety Considerations
Secure Your Seat
The Aesthetic Medicine Convention is now less than a week away.
Join leading experts, gain critical regulatory insight, and stay ahead in an increasingly complex and fast-moving industry.
Extended Early Bird – Save 25% (ending soon):
Qualified Medical Practitioners
2 Days – R3 375 (Save R1 125)
1 Day – R2 625 (Save R875)
Aesthetic Medicine Practice Staff
2 Days – R1 875 (Save R625)
1 Day – R1 125 (Save R375)
Doctors attending the 2-day programme can earn 12 CPD points (10 Clinical, 2 Ethical).
Book a two-day ticket and stand a chance to win your money back plus R2,000 cash.
Seats are limited.
Book now to secure your place.
It’s interesting how similar this is to the early days of cosmetic injectables—everyone wanted them before the importance of proper assessment sank in. If GLP-1s are being handed out without bloodwork or follow-up, that’s just repeating old mistakes. Medical oversight isn’t a technicality; it’s the whole point.
flux 3
I found myself comparing this to how I view Botox or filler appointments. Those are often quick, skill-based procedures, but a GLP-1 prescription seems to demand far more follow-up care and metabolic monitoring. That distinction is easy to overlook.
I've seen friends get these injections from online clinics without a proper workup. The article's point about oversight really hits home; one of them ended up with severe nausea and no plan for managing it. Glad to see this being discussed more seriously.
visual creation tool
The oversight issue is exactly why we need stricter guardrails around GLP-1s—when non-medical sellers enter the mix, patient safety gets lost in the profit margin. Curious to see how regulators respond, and I've been tracking the latest updates on https://omni-gemini.net
The oversight gap is exactly why we need stricter guardrails around GLP-1s—when non-medical sellers enter the mix, patient safety gets pushed aside for profit. Curious how clinics are tightening their protocols, so I've been checking out https://grok-ai-video.com